AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diederen, B. M. W.
Right arrow Articles by Kluytmans, J. A. J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diederen, B. M. W.
Right arrow Articles by Kluytmans, J. A. J. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2006, p. 3189-3191, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00526-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus, Including Heterogeneously Glycopeptide-Resistant Strains

Bram M. W. Diederen,2* Inge van Duijn,1 Piet Willemse,1 and Jan A. J. W. Kluytmans1

Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, The Netherlands,1 Laboratory of Medical Microbiology, St. Elisabeth Hospital, Tilburg, The Netherlands2

Received 28 April 2006/ Returned for modification 7 May 2006/ Accepted 9 June 2006


   ABSTRACT
Top
 Abstract
Text
 References
 
The purpose of the present study was to assess the in vitro activity of daptomycin against a well-defined collection of methicillin-resistant Staphylococcus aureus (MRSA) isolates (n = 98), including heterogeneously glycopeptide-resistant MRSA (hGISA) strains. Susceptibility testing was performed by using the Etest system. Daptomycin was potent against both glycopeptide-susceptible and hGISA strains.


   TEXT
Top
 Abstract
 Text
References
 
Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial pathogen (1). According to a report from the National Nosocomial Infection Surveillance System, ca. 60% of all S. aureus isolated from patients in intensive care units in U.S. hospitals were methicillin resistant in 2003 (12). Infections caused by MRSA strains are associated with longer hospital stay, more days of antibiotic administration, and higher costs than infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) strains (1, 5). Reports of vancomycin intermediately susceptible S. aureus (VISA), first isolated in Japan in 1997 (9), and vancomycin-resistant S. aureus in the United States (4) caused widespread alarm among physicians since it was feared that we are entering an era of untreatable S. aureus infections. Vancomycin remains the standard for treating most MRSA infections; however, concerns over increases in the rates of heteroresistance and tolerance to this agent, combined with its pharmacodynamic and clinical shortcomings and the increasingly important role of gram-positive bacterial infections in clinical medicine, have motivated the development of newer agents. Daptomycin is a cyclic lipopeptide antibiotic that is rapidly bactericidal in vitro against a broad spectrum of gram-positive bacteria. Its unique mechanism of action involves calcium-dependent binding to the bacterial plasma membrane and disruption of membrane function (3).

The purpose of the present study was to assess the in vitro activity of daptomycin against MRSA isolates collected in The Netherlands using a well-defined collection of strains that included heterogeneously glycopeptide-resistant MRSA strains (hGISA).

The MRSA isolates were collected in The Netherlands between 1989 and 1998 and are part of the MRSA strain collection of the National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands. Identification as S. aureus and methicillin resistance were determined by duplex PCR for the mecA gene and coagulase gene as described previously (10, 19). In the present study a total of 98 strains were tested, including 19 hGISA strains, which were determined by using modified population analysis profiles (20, 21). The MIC of daptomycin was determined by using the Etest system (AB Biodisk, Solna, Sweden) with a concentration range of 0.016 to 256 µg/ml. The daptomycin Etest contained a concentration gradient of daptomycin with a standard amount of calcium throughout the strip. E-test strips were applied to the surface of 150-mm Mueller-Hinton agar plates. Plates were incubated at 35°C in ambient air for 18 to 24 h prior to reading the MIC results. The MICs of the following antimicrobial agents were determined simultaneously: vancomycin, teicoplanin, gentamicin, cotrimoxazole, ciprofloxacin, erythromycin, clindamycin, and rifampin. All MICs were determined with the Etest system. For vancomycin and teicoplanin, the Etest strips were placed on brain heart infusion agar, and a large inoculum (no. 2 McFarland standard) and an extended incubation time (48 h) were used to be able to detect hGISA isolates. Isolates were categorized as susceptible or resistant to an antimicrobial agent according to the breakpoints published by the Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for Clinical Laboratory Standards) (11). The breakpoint for daptomycin is 1 mg/liter for S. aureus (both methicillin-resistant and methicillin-susceptible strains).

For 98 MRSA isolates, the MIC range for daptomycin was 0.125 to 1.0 µg/ml (Table 1 and Fig. 1), with MICs at which 50 and 90% of the isolates tested are inhibited (MIC50 and MIC90, respectively) of 0.38 and 0.75 µg/ml, respectively. The MIC range for daptomycin against hGISA isolates was 0.19 to 1.0 µg/ml. The MICs of MRSA isolates for other antibiotics are outlined in Table 1. The MICs of daptomycin correlated weakly, but statistically significantly, with those of vancomycin (r = 0.318; P = 0.001) and teicoplanin (r = 0.334; P = 0.001) by using log-linear regression analysis.


View this table:
[in this window]
[in a new window]
  		TABLE 1. In vitro activities of daptomycin and other antimicrobial agents against 98 MRSA strains isolated in The Netherlands

 

Figure 1
View larger version (16K):
[in this window]
[in a new window]
  		FIG. 1. MICs for daptomycin for 79 glycopeptide-susceptible MRSA strains (A) and 19 heterogeneously glycopeptide-resistant MRSA strains (hGISA) (B) collected in The Netherlands as determined by using the Etest system. Gray bars, total number of isolates tested; black bars, percentage of the total tested.

 
The results are generally comparable with other data on European and North American antibiotic-resistant clinical isolates that were phenotypically characterized (2, 8, 14, 18). In a recent study, the in vitro activity of daptomycin against 337 gram-positive European clinical isolates with known resistance genes was determined (7). MICs were determined by CLSI methodology using microtiter plates containing antibiotic solutions and physiologic concentrations of Ca2+ (50 µg/ml). For 38 MRSA isolates, the MIC range for daptomycin was 0.03 to 0.5 µg/ml, with MIC50 and MIC90 values for the isolates tested of 0.25 and 0.5 µg/ml, respectively. The daptomycin MICs determined in our study appear to be slightly higher. One explanation for these results may be the limited number of isolates tested in the study by Fluit et al. (7) and because we selected for hGISA in our study.

It appears that S. aureus with reduced susceptibility to vancomycin also exhibits reduced susceptibility to daptomycin (13, 16). In concordance with findings by Cui et al. (6), we found a positive correlation between reduced daptomycin susceptibility and reduced susceptibility to glycopeptides. Although the correlation coefficient is relatively weak, it is highly significant. In the study by Cui et al., the reduction of daptomycin susceptibility showed a strong correlation with the increment of cell wall thickness. The level of daptomycin susceptibility correlated strongly and positively with that of vancomycin susceptibility (r = 0.814; P < 0.0001) and with cell wall thickness (r = 0.883; P < 0.0001). It is conceivable that the changes mediating reduced susceptibility to vancomycin in S. aureus, including a thickened cell wall, changes in cellular metabolism, and enhanced cell wall turnover, interfere with the antimicrobial action of daptomycin. In a recent study, the bactericidal activity of vancomycin and daptomycin against 105 well-characterized S. aureus strains with decreased susceptibility against vancomycin (88 hGISA and 17 VISA), as well as 105 vancomycin-suseptible MRSA strains (VSSA) were tested by using a CLSI broth microdilution method (15). All VSSA and hGISA strains were inhibited by ≤1 mg of daptomycin/liter. However, a slight skewing toward higher daptomycin MIC results was noted when the hGISA (MIC50 = 0.5 mg/liter, and MIC90 = 1 mg/liter) and VISA (MIC50 = 1 mg/liter, and MIC90 = 2 mg/liter) were compared to VSSA strains (MIC50 and MIC90 = 0.5 mg/liter). Among the 17 VISA strains evaluated, 7 (41.2%) showed a daptomycin MIC of 2 mg/liter and 1 (5.9%) had a daptomycin MIC of 4 mg/liter. However, all daptomycin minimum bactericidal concentration (MBC) results were at the MIC or twofold higher than the MIC, and the MBC/MIC ratios were not significantly affected by the susceptibility to vancomycin. Conversely, 69.3% of hGISA strains and all VISA strains showed a vancomycin MBC/MIC ratio consistent with tolerance (tolerance was defined as an MBC/MIC ratio of ≥32 or ≥16 with an associated MBC at ≥32 mg/liter for vancomycin). The increased MIC of daptomycin associated with hGISA is therefore most likely not caused by an intrinsic resistance mechanism but by the thickening of the cell wall. Further studies are needed before final conclusions can be made.

In conclusion, daptomycin exhibits broad in vitro activity against a collection of MRSA strains collected in The Netherlands. The in vitro data presented in this and other studies, together with promising clinical results (17), show that daptomycin is a valuable new addition to the arsenal of antimicrobial agents for the treatment of infections caused by gram-positive microorganisms.


   FOOTNOTES
 
* Corresponding author. Mailing address: Laboratory of Medical Microbiology, St. Elisabeth Hospital, P.O. Box 747, 5000 AS Tilburg, The Netherlands. Phone: 31 13 539 2655. Fax: 31 13 544 1264. E-mail: b.diederen{at}elisabeth.nl. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Archer, G. L. 1998. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis. 26:1179-1181.[Medline]
  2. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.[Abstract/Free Full Text]
  3. Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. 38:994-1000.[CrossRef][Medline]
  4. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, S. K. Fridkin, et al. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.[Free Full Text]
  5. Cosgrove, S. E., Y. Qi, K. S. Kaye, S. Harbath, A. W. Karchmer, and Y. Carmeli. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26:166-174.[CrossRef][Medline]
  6. Cui, L., E. Tominaga, H. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.[Abstract/Free Full Text]
  7. Fluit, A. C., F. J. Schmitz, J. Verhoef, and D. Milatovic. 2004. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob. Agents Chemother. 48:1007-1011.[Abstract/Free Full Text]
  8. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2002. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49:467-470.[Abstract/Free Full Text]
  9. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.[Free Full Text]
  10. Kluytmans, J., A. Van Griethuysen, P. Willemse, and P. Van Keulen. 2002. Performance of CHROMagar selective medium and oxacillin resistance screening agar base for identifying Staphylococcus aureus and detecting methicillin resistance. J. Clin. Microbiol. 40:2480-2482.[Abstract/Free Full Text]
  11. National Committee for Clinical Laboratory Standards. 2006. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S16. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  12. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.[CrossRef][Medline]
  13. Patel, J. B., L. A. Jevitt, J. Hageman, L. C. McDonald, and F. C. Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.[CrossRef][Medline]
  14. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.[Abstract/Free Full Text]
  15. Sader, H. S., P. R. Rhomberg, and R. N. Jones. 2005. Bactericidal activity of vancomycin and daptomycin tested against heterogeneous and homogeneous vancomycin-intermediate Staphylococcus aureus (hVISA and VISA) strains, p. 978. In Program and abstracts book, 15th European Congress of Clinical Microbiology and Infectious Diseases. European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark.
  16. Sakoulas, G., J. Alder, G. M. Eliopoulos, R. C. Moellering, C. Thauvin-Eliopoulos, and G. M. Eliopoulos. 2005. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
  17. Schriever, C., C. Fernandez, K. Rodvold, and L. Danziger. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62:1145-1158.[Abstract/Free Full Text]
  18. Silverman, J. A., N. Oliver, O. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.[Abstract/Free Full Text]
  19. van Griethuysen, A. J., M. Pouw, N. van Leeuwen, M. Heck, P. Willemse, A. Buiting, and J. Kluytmans. 1999. Rapid slide latex agglutination test for detection of methicillin resistance in Staphylococcus aureus. J. Clin. Microbiol. 37:2789-2792.[Abstract/Free Full Text]
  20. van Griethuysen, A. J., A. van't Veen, A. Buiting, T. Walsh, and J. Kluytmans. 2003. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J. Clin. Microbiol. 41:2487-2491.[Abstract/Free Full Text]
  21. Walsh, T. R., A. Bolmström, A. Qwärnström, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, September 2006, p. 3189-3191, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00526-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diederen, B. M. W.
Right arrow Articles by Kluytmans, J. A. J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diederen, B. M. W.
Right arrow Articles by Kluytmans, J. A. J. W.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS